Bone Biologics Corporation is a clinical-stage developer of orthobiologic products for spine fusion markets. The Company is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
äŒæ¥ã³ãŒãBBLG
äŒç€ŸåBone Biologics Corp
äžå Žæ¥Nov 27, 2015
æé«çµå¶è²¬ä»»è
ãCEOãFrelick (Jeffrey)
åŸæ¥å¡æ°2
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Nov 27
æ¬ç€Ÿæåšå°2 Burlington Woods Dr Ste 100
éœåžBURLINGTON
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·01803-4551
é»è©±çªå·17815524452
ãŠã§ããµã€ãhttps://www.bonebiologics.com/
äŒæ¥ã³ãŒãBBLG
äžå Žæ¥Nov 27, 2015
æé«çµå¶è²¬ä»»è
ãCEOãFrelick (Jeffrey)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã